Kyverna Therapeutics, Inc.
KYTX Nasdaq
SEC CIK 1994702
Follow Kyverna Therapeutics
Weekly email: filings, results
Net income
−$41.9M
−14% vs same quarter last year
EPS, diluted
−$0.68
+20% vs same quarter last year
Operating cash flow
−$35.4M
+18.4% vs same quarter last year
Operating income
−$42.9M
−10.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$161.3M |
| FY24 | −$127.5M |
| FY23 | −$60.4M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$153.7M |
| FY24 | −$116.5M |
| FY23 | −$53M |
| FY22 | - |